The Global Inhaled Nitric Oxide NO Delivery Systems Market size was valued at $2.8 billion in 2018 and is projected to grow at a CAGR of 5.3% from 2021 to 2028. The growth in this market will be supported by the rising prevalence of chronic respiratory diseases such as asthma and COPD, increasing awareness about the benefits of inhaled nitric oxide therapy among patients with acute or chronic respiratory conditions, improving product innovation in terms of cost-effective delivery systems for inhalation drugs that can provide accurate doses adjusted on body weight or disease severity and growing demand from emerging economies.
Inhaled Nitric Oxide Delivery Systems are the medical devices that provide inhaled nitric oxide therapy to patients with acute or chronic respiratory conditions. They come in two types: general type and intelligent type. These devices are used to treat respiratory conditions which include pulmonary hypertension, chronic obstructive pulmonary disease, and other lung diseases. These devices can also be used in cardiology procedures for the treatment of coronary artery disease when combined with a balloon catheter or stent placement.
On the basis of Types, the market is segmented into General Type and Intelligent Type. General type devices are further segmented into nasal types, oral types, and others (nasal hoods). On the other hand. intelligent type is primarily split on the basis of inhaler device, nebulizer device, and system-inhalers.
The general type is an inhaler that delivers nitric oxide gas directly into the lungs without using electronics while intelligent types provide inhaled nitric oxide therapy through electronic controls by monitoring patient's breathing patterns and adjusting Nitric Oxide concentration accordingly. General type devices are used to deliver a continuous flow of nitric oxide gas from an external tank. They typically provide stable levels of oxygen and humidity which is required for the therapy treatment.
Intelligent type delivery systems allow precise adjustment in terms of dose based on weight or disease severity. This is done by incorporating a microprocessor that can control the dosage delivered through inhalation. The intelligent type also has built-in sensors that monitor a patient's breathing patterns with instantaneous feedback information to adjust if necessary before delivering nitric oxide gas into the lungs.
On the basis of Applications, the market is segmented into Infant Applications & Adult applications.
The use of inhaled nitric oxide NO delivery systems in infant applications is expected to witness considerable growth during the forecast period from 2021 to 2028. This can be attributed primarily due to the increasing prevalence of respiratory tract infections and other related diseases, which are substantially worsening with time. As a result, physicians prescribe health care professionals such as neonatologists or pediatricians for the treatment of newborns suffering from these ailments by administering prophylactic medications that act directly on the lungs (e.g., bronchodilators) or through indirect effects (e.g., steroids). To prevent infants from premature airway closure at birth-a condition known as persistent pulmonary hypertension syndrome-physicians often administer inhaled nitric oxide NO delivery system. A NO delivery system is a device, which delivers an aerosolized drug (e.g., nitric oxide) to the respiratory tract for therapeutic purposes.
The global inhaled nitric oxide NO delivery systems market for adult application is expected to grow at a CAGR of over 27% from 2021 to 2028. This growth can be attributed to the use of inhaled nitric oxide NO delivery systems for managing respiratory diseases like asthma, chronic obstructive pulmonary disease (COPD), and other pulmonary vasculitis disorders as well as bronchiectasis. In addition, it has been found that inhalers are easy and comfortable to use by patients compared with nebulizers or metered-dose inhalers.
On the basis of Region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and the Middle East & Africa. The North American region is expected to be the largest market for inhaled nitric oxide NO delivery systems in 2021. This growth can be attributed to factors like increasing awareness about this technology among physicians as well as a growing number of respiratory diseases afflicting adults such as COPD and asthma which are more prevalent in countries like America than in other regions.
Up Market Research published a new report titled “Inhaled Nitric Oxide NO Delivery Systems Market research report which is segmented by Types (General Type, Intelligent Type), By Applications (Infant, Adult), By Players/Companies International Biomedical, Praxair (NoxBox), Getinge, SLE, VERO Biotech”.
|Report Attributes||Report Details|
|Report Title||Inhaled Nitric Oxide NO Delivery Systems Market Research Report|
|By Type||General Type, Intelligent Type|
|By Application||Infant, Adult|
|By Companies||International Biomedical, Praxair (NoxBox), Getinge, SLE, VERO Biotech|
|Regions Covered||North America, Europe, APAC, Latin America, MEA|
|Historical Year||2018 to 2019 (Data from 2010 can be provided as per availability)|
|Number of Pages||241|
|Number of Tables & Figures||169|
|Customization Available||Yes, the report can be customized as per your need.|
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
The market is segmented by Type General Type, Intelligent Type and By Application Infant, Adult.
Some of the companies that are profiled in this report are:
Inhaled Nitric Oxide NO Delivery Systems Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
We have studied the Inhaled Nitric Oxide NO Delivery Systems Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
Reasons to Purchase the Inhaled Nitric Oxide NO Delivery Systems Market Report:
Some other reports from this category!